H-亮氨酰-苯丙氨酰胺盐酸盐 | 74214-38-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: H-亮氨酰-苯丙氨酰胺盐酸盐
• 英文名称: Leu-Phe-NH2 hydrochloride
• 英文别名: HCl*Leu-Phe-NH2；L-leucyl-L-phenylalaninamide hydrochloride；H-Leu-Phe-NH2 hydrochloride；leucylphenylalaninamide hydrochloride；H-Leu-Phe-NH2 HCl；(2S)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-4-methylpentanamide;hydrochloride
• CAS: 74214-38-3
• 化学式: C₁₅H₂₃N₃O₂*ClH
• 分子量: 313.827
• InChiKey: WQKTWSKQUPVUIU-QNTKWALQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.14
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  99.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Leu-Phe-NH2 HCl
Synonyms: (2S)-2-amino-N-[(1S)-1-carbamoyl-2-phenylethyl]-4-methylpentanamide HCl

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Leu-Phe-NH2 HCl
CAS number: 74214-38-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H24ClN3O2
Molecular weight: 313.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  H-亮氨酰-苯丙氨酰胺盐酸盐 在 盐酸 、 二苯基膦叠氮化物 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 98.0h， 生成 (phenoxyacetyl)-His-Sta-Leu-Phe-NH2
  参考文献：
  名称：

  肾素抑制剂。包含新的他汀类药物类似物的亚纳摩尔竞争性过渡态类似物抑制剂的合成。

  摘要：

  合成了肾素八肽底物的类似物，其中用（3S，4S）-4-氨基-3-羟基-6-甲基庚酸（statine，Sta）取代易裂二肽将底物序列转变为有效的过渡态类似物，肾素的竞争性抑制剂。Sta的环己基丙氨酰基类似物（3S，4S）-4-氨基-5-环己基-3-羟基戊酸（ACHPA）的合成和掺入提供了迄今为止报道的最有效的肾素抑制剂，包括N-异戊基-L-组氨酸-L-脯氨酰基-L-苯丙氨酰基-L-组氨酸-ACHPA-L-亮氨酰-L-苯丙氨酰胺[Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2,3]，肾素抑制Ki = 1.6 X 10（-10）M（人肾素），IC50 = 1.7 X 10（-10）M（人血浆肾素），IC50 = 1.9 X 10（-9）M（犬血浆肾素）和IC50 = 2.1 X 10（-8）M（大鼠血浆肾素）。含有ACHPA的这种抑制剂3，与人肾素的效价比含Sta的抑

  DOI：

  10.1021/jm00150a007
• 作为产物：
  描述：

  L-苯丙氨酰胺 在 盐酸 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 H-亮氨酰-苯丙氨酰胺盐酸盐
  参考文献：
  名称：

  肾素抑制剂。包含新的他汀类药物类似物的亚纳摩尔竞争性过渡态类似物抑制剂的合成。

  摘要：

  合成了肾素八肽底物的类似物，其中用（3S，4S）-4-氨基-3-羟基-6-甲基庚酸（statine，Sta）取代易裂二肽将底物序列转变为有效的过渡态类似物，肾素的竞争性抑制剂。Sta的环己基丙氨酰基类似物（3S，4S）-4-氨基-5-环己基-3-羟基戊酸（ACHPA）的合成和掺入提供了迄今为止报道的最有效的肾素抑制剂，包括N-异戊基-L-组氨酸-L-脯氨酰基-L-苯丙氨酰基-L-组氨酸-ACHPA-L-亮氨酰-L-苯丙氨酰胺[Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2,3]，肾素抑制Ki = 1.6 X 10（-10）M（人肾素），IC50 = 1.7 X 10（-10）M（人血浆肾素），IC50 = 1.9 X 10（-9）M（犬血浆肾素）和IC50 = 2.1 X 10（-8）M（大鼠血浆肾素）。含有ACHPA的这种抑制剂3，与人肾素的效价比含Sta的抑

  DOI：

  10.1021/jm00150a007

文献信息

• Fluoro ketone containing peptides as inhibitors of human renin
  作者：Karen Fearon、Andreas Spaltenstein、Paul B. Hopkins、Michael H. Gelb

  DOI：10.1021/jm00392a016

  日期：1987.9

  prepared and found to be a potent inhibitor of human renin. This compound contains a difluoromethylene ketone group that exists predominantly in the hydrated form in water. The difluorostatone-containing peptide is 7-fold and 22-fold more potent than the analogous statine- and statone-containing peptides, respectively. Structure/activity analysis of the most potent inhibitor was carried out by replacing

  已制备了五肽BOC-Phe-Phe-二氟statone-Leu-Phe-NH2，发现它是人肾素的有效抑制剂。该化合物包含主要以水合形式存在于水中的二氟亚甲基酮基。含二氟statone的肽的效力分别比类似的含statine和statone的肽高7倍和22倍。最有效的抑制剂的结构/活性分析是通过用反式烯烃取代某些肽键进行的。在所有情况下，均观察到与肾素的结合显着丧失。已经报道了许多含他汀类的肾素抑制剂，这项工作表明用二氟他酮替代他汀会产生更有效的化合物。
• Novel uridin-2′-yl carbamates: synthesis, incorporation into oligodeoxyribonucleotides, and remarkable fluorescence properties of 2′-pyren-1-ylmethylcarbamateElectronic supplementary information (ESI) available: Additional experimental data for compounds 3, 5 and 6. See http://www.rsc.org/suppdata/p1/b1/b111434b/
  作者：Vladimir A. Korshun、Dmitry A. Stetsenko、Michael J. Gait

  DOI：10.1039/b111434b

  日期：2002.4.9

  A convenient method for the preparation of uridin-2′-yl carbamate derivatives is described. The stable 2′-O-(imidazol-1-ylcarbonyl)-3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)uridine, prepared from uridine, was treated with primary or secondary aliphatic amines to give 2′-carbamates in high yield. After 3′,5′-O-deprotection with triethylamine trihydrofluoride, 5′-O-dimethoxytritylation, and 3′-O-phosphitylation with bis(N,N-diisopropylamino)-2-cyanoethoxyphosphine, modified phosphoramidites were obtained and used in machine-assisted synthesis of modified oligodeoxynucleotides containing uridin-2′-yl carbamate residues bearing various N-substituents. The influence of uridin-2′-yl carbamate moieties on the stability of modified oligonucleotide duplexes with complementary DNA and RNA was studied by thermal denaturation experiments. Pyrene-modified oligonucleotides showed a considerable increase in fluorescence intensity upon hybridisation to complementary RNA and interesting binding properties when hybridised to a mismatched DNA.

  描述了一种制备尿苷-2′-基脲甲酸酯衍生物的便捷方法。由尿苷制备的稳定2′-O-(咪唑-1-酰基)-3′,5′-O-(四异丙基二硅氧烷-1,3-二基)尿苷与初级或次级脂肪胺反应，生成高产率的2′-脲甲酸酯。在用三乙胺氟化氢进行3′,5′-O-去保护后，再进行5′-O-二甲氧基三苯甲基化和与双(N,N-二异丙基氨基)-2-氰基乙氧基膦的3′-O-磷酸化，获得了改性磷酰胺酯，并用于机器辅助合成含有各种N-取代基的尿苷-2′-基脲甲酸酯残基的改性寡脱氧核苷酸。通过热变性实验研究了尿苷-2′-基脲甲酸酯部分对改性寡核苷酸与互补DNA和RNA的双链稳定性影响。修饰的芘寡核苷酸在与互补RNA杂交时显示出显著的荧光强度增加，并在与错配DNA杂交时表现出有趣的结合特性。
• HIV protease inhibitors useful for the treatment of aids
  申请人：MERCK & CO. INC.

  公开号：EP0337714A2

  公开（公告）日：1989-10-18

  Compounds of the form wherein A is an amine protecting group commonly employed in peptide synthesis, G a dipeptide isostere, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  描述了以下形式的化合物 其中 A 是肽合成中常用的胺保护基团，G 是二肽异构体，B 是氨基酸或其类似物，J 是小末端基团。这些化合物作为化合物、药学上可接受的盐、药物组合成分，无论是否与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用，都可用于抑制 HIV 蛋白酶、预防或治疗 HIV 感染以及治疗 AIDS。还描述了治疗艾滋病的方法和预防或治疗艾滋病毒感染的方法。
• Stereoselective Synthesis of Photoreactive Peptidomimetic γ-Secretase Inhibitors
  作者：Jiong Chun、Ye Ingrid Yin、Guangli Yang、Leonid Tarassishin、Yue-Ming Li

  DOI：10.1021/jo0486948

  日期：2004.10.1

  The first asymmetric synthesis of novel, potent photoreactive gamma-secretase inhibitors 2 and 3 has been accomplished. Two stereoselective methods for the preparation of lactone 9 are described. Protected benzophenone intermediate 19 is prepared via an aldol-elimination reaction followed by a PtO2-catalyzed asymmetric hydrogenation. Two routes leading from 19 to compounds 2 and 3 are evaluated. The application of 3 as an activity-based probe has been demonstrated by localizing gamma-secretase activity in the plasma membrane of intact cells.
• FEARON, KAREN;SPALTENSTEIN, ANDREAS;HOPKINS, PAUL B.;GELB, MICHAEL H., J. MED. CHEM., 30,(1987) N 9, 1617-1622
  作者：FEARON, KAREN、SPALTENSTEIN, ANDREAS、HOPKINS, PAUL B.、GELB, MICHAEL H.

  DOI：——

  日期：——